Abstract:Abstract Patients with solid tumor usually do not respond to retinoic acid (RA)-based differentiation therapy because RA-resistance often develops. The goal of this study is to develop metabolic intervention strategies that target the cancer epigenome and overcome tumor resistance to differentiation therapy. Experimental procedures: We classified our neuroblastoma (NB) cell line collection into two categories: RA-sensitive cell lines and RA-resistant cell lines. Metabolic intervention agents were combined with RA to treat the RA-resistance cells. Chromatin markers including histone acetylations and methylations were determined using immunoblot. Global DNA methylation were accessed using dot blot. NB cell differentiation were quantified with neurite counting and immunofluorescence staining for NB differentiation marker β-tubulin III. Retinoic acid receptor (RAR) and neuron differentiation marker expression were measured using q-PCR. Summary of findings: Unlike the RA-sensitive NB cells, the RA-resistant cells did not show morphological change or proliferation arrest upon RA treatment. Previously we discovered that glycerol triacetate (GTA) supplementation restored histone acetylation and chromatin accessibility to reactivate the expression of differentiation markers and the RA-induced neuron differentiation program under hypoxia. However, the combination of GTA and RA did not induce proliferation arrest or morphologic change in RA-resistant cells. Interestingly, the combination of RA and the substrate of DNA demethylase, α-ketoglutarate (αKG), significantly induced neuronal differentiation in RA-resistant cells. RAR and differentiation markers expression were also restored by RA+αKG combination. αKG treatment rapidly reduced global 5-methylcytosine (5mC) levels within 1 hour. Although GTA alone or RA+GTA did not induce differentiation, adding GTA in combination with RA and αKG further enhanced the differentiation morphology change in resistant cells. In addition, αKG and GTA supplementation had a synergistic effect in reducing the clonogenic expansion of RA-resistant cells when combined with RA, suggesting that the RA+αKG+GTA combination inhibits self-renewal of RA-resistance NB cells. However, in RA-sensitive cells, αKG could not restore RAR repression caused by hypoxia, probably due to the elevated NADH/NAD+ ratio that favors the conversion of αKG to 2-hydroxyglutarate (2HG), which causes DNA hypermethylation. Conclusions: (1) Unlike hypoxia-induced resistance, which was mainly due to histone deacetylation, DNA methylation is the major cause of resistance in RA-resistant NB cells. (2) αKG+GTA combination effectively reduces DNA methylation and increases histone acetylation to promote RA-sensitivity in RA-resistant NB cells. Citation Format: Haowen Jiang, Yang Li, Michela Yip, Joshua Gruber, Albert Li, Jiangbin Ye. Developing metabolic intervention strategies to reprogram neuroblastoma epigenome and overcome tumor resistance to differentiation therapy [abstract]. In: Abstracts: AACR Special Virtual Conference on Epigenetics and Metabolism; October 15-16, 2020; 2020 Oct 15-16. Philadelphia (PA): AACR; Cancer Res 2020;80(23 Suppl):Abstract nr PR09.

The MYCN inhibitor BGA002 restores the retinoic acid response leading to differentiation or apoptosis by the mTOR block in MYCN-amplified neuroblastoma

Synergy of retinoic acid and BH3 mimetics in MYC(N)-driven embryonal nervous system tumours

Retinoic acid and TGF-β signalling cooperate to overcome MYCN-induced retinoid resistance

TL-118 and gemcitabine drug combination display therapeutic efficacy in a MYCN amplified orthotopic neuroblastoma murine model--evaluation by MRI

Enhancing Retinoic Acid-mediated Effects Through Inhibition of CYP26A1, CYP26B1 and HGF Signaling in Neuroblastoma Cells

Mitochondrial uncoupler and retinoic acid synergistically induce differentiation and inhibit proliferation in neuroblastoma

Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination

The MDM2 inhibitor CGM097 combined with the BET inhibitor OTX015 induces cell death and inhibits tumor growth in models of neuroblastoma

The Proteasome Inhibitor Bortezomib Enhances Atra-Induced Differentiation Of Neuroblastoma Cells Via The Jnk Mitogen-Activated Protein Kinase Pathway

A Novel Therapeutic Mechanism of Imipridones ONC201/ONC206 in MYCN-Amplified Neuroblastoma Cells via Differential Expression of Tumorigenic Proteins

Combined mitoxantrone and anti-TGFβ treatment with PD-1 blockade enhances antitumor immunity by remodelling the tumor immune landscape in neuroblastoma

Combination of metronomic cyclophosphamide and dietary intervention inhibits neuroblastoma growth in a CD1-nu mouse model

Evaluation of a Combinatorial Immunotherapy Regimen That Can Cure Mice Bearing MYCN-Driven High-Risk Neuroblastoma That Resists Current Clinical Therapy

Preclinical spheroid models identify BMX as a therapeutic target for metastatic MYCN nonamplified neuroblastoma

Novel miRNA-inducing drugs enable differentiation of retinoic acid-resistant neuroblastoma cells

Abstract PR09: Developing Metabolic Intervention Strategies to Reprogram Neuroblastoma Epigenome and Overcome Tumor Resistance to Differentiation Therapy

Preclinical Therapeutic Efficacy of RAF/MEK/ERK and IGF1R/AKT/mTOR Inhibition in Neuroblastoma

Abstract 5344: High-throughput CRISPR-Cas9 knockout screens identify loss of miRNA1304-5p targeting the RAS/MAPK pathway as a modulator of resistance to ALK inhibitors in high-risk neuroblastoma

PROTAC Bromodomain Inhibitor ARV-825 Displays Anti-Tumor Activity in Neuroblastoma by Repressing Expression of MYCN or c-Myc

Synergistic Effect of Statins and Abiraterone Acetate on the Growth Inhibition of Neuroblastoma via Targeting Androgen Receptor

Combining immunotherapy with high-dose radiation therapy (HDRT) significantly inhibits tumor growth in a syngeneic mouse model of high-risk neuroblastoma